(0) CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc.(VRTX) said Wednesday that the U.S. Food and Drug Administration approved expanded use of Trikafta to include children with cystic fibrosis or CF ages 6 through 11 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator or CFTR gene or a mutation in the CFTR gene that is responsive to TRIKAFTA based on in vitro data. The FDA previously approved Trikafta for use in people with cystic fibrosis 12 years and older with at least one copy of the F508del mutation or one copy of a mutation that is responsive in vitro.